0HI3.L StockTwits Mentions

Track 0HI3.L's AI-powered predictions, market trends, and investment insights.

0HI3.L AI Prediction 0HI3.L Sentiment 0HI3.L Reddit

Mock Tradesimulated, no real money

You don't hold 0HI3.L in your mock portfolio yet.

0HI3.L StockTwits Mentions

Track 0HI3.L's AI-powered predictions, market trends, and investment insights.

0HI3.L AI Prediction 0HI3.L Sentiment 0HI3.L Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)+3.6%

Price (7d)+5.4%

Volume vs avg1.3x

Reddit mentions vs 7D-100%

Volatility vs normal0.8x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 2K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~$71.33 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

0HI3.L AI Stock Analysis

Financial Performance

bearish

Arrowhead Pharmaceuticals is currently unprofitable, as reflected in its negative EPS and negative P/E ratio. The valuation multiple based on a negative P/E (-68.88) suggests investors are paying a high price relative to current losses, implying expectations of future growth but no present earnings support. Without positive net income or profitability ratios, the financial picture leans weak in the near term and depends heavily on future pipeline success.

Negative EPS of -1.08 and a P/E ratio of -68.88 indicate the company is loss-making and that the stock price is high relative to current earnings power.
Lack of profitability means traditional metrics like net margin, ROE, and ROA are likely negative, underscoring reliance on external capital and future commercialization rather than current cash generation.
The investment case is driven more by long-term R&D and pipeline prospects than by present financial strength, which is a structurally higher-risk profile typical of development-stage biopharma.

Stock Price & Technicals

neutral

The stock is trading at $74.05 with only a 0.1% decline over the last month, indicating short‑term price stability. An RSI of 50.61 signals neither overbought nor oversold conditions, and the current price is well above the 200‑day moving average of $31.06, pointing to a strong longer‑term uptrend but also a potentially extended move. Overall, technicals suggest a consolidating stock after a significant rally, with no clear near‑term directional bias.

Price at $74.05 is essentially flat over the last month (-0.1%), suggesting consolidation rather than strong momentum in either direction.
RSI at 50.61 is neutral, implying balanced buying and selling pressure with no immediate signal of exhaustion or capitulation.
The stock trades far above its 200‑day moving average ($31.06), confirming a robust longer‑term uptrend but also indicating the possibility of elevated volatility or mean‑reversion risk if sentiment shifts.

Alternative Data Signals

bullish

Alternative data for Arrowhead Pharmaceuticals show signs of operational expansion and growing professional interest. Job openings at 274, up 46.5% month over month, point to aggressive hiring and likely pipeline or organizational scaling. LinkedIn followers are sizable at over 99k and growing 3.2% in 90 days, suggesting increasing engagement from industry professionals and talent, while web traffic and social channels are stable to modestly positive.

Job postings at 274 with a 46.5% month‑over‑month increase strongly indicate expansion in R&D, operations, or commercialization capacity, typically a constructive signal for future activity.
LinkedIn following of 99,344 with 3.2% growth over 90 days reflects rising professional awareness and interest, often correlated with hiring, partnerships, and corporate visibility.
Web traffic of 55,409 monthly visitors and steady to slightly growing Twitter/X and Facebook audiences suggest stable baseline engagement, with LinkedIn being the standout growth channel most relevant for a biotech company.

Conclusion

neutral

Arrowhead Pharmaceuticals presents a mixed picture: technically strong over the longer term and showing clear signs of organizational growth, but still fundamentally unprofitable and valued on expectations rather than earnings. The stock’s recent price consolidation and neutral RSI, combined with substantial hiring and professional interest, suggest cautious optimism balanced by the inherent risks of a loss‑making biotech. Overall, the setup appears neutral, skewing toward constructive if the pipeline and execution continue to justify the current valuation.

Unprofitable financials and a high negative P/E keep the risk profile elevated and place significant weight on future clinical and commercial milestones.
Strong long‑term price performance, neutral near‑term technicals, and bullish alternative data (especially hiring and LinkedIn growth) indicate a company in expansion mode, but not yet de‑risked enough to warrant an outright bullish stance.

AI Score

Hold

Alternative7

Fundamental7

Technical6

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold 0HI3.L in your mock portfolio yet.